Ankyra Announces Trial Agreement with Regeneron to Evaluate ANK-101
89% estimated event-free survival at one year among patients with stage II to IV resectable CSCC who received Libtayo prior to surgery in a Phase 2 trial No disease recurrence among the 51% of...
OncoNano and Regeneron Enter into Clinical Trial Supply Agreement for Use of Libtayo® (cemiplimab) in ONM-501 Study
Regeneron is exploring next steps with its PSMA/CD28 bispecific antibody development in prostate cancer after two patient deaths in a combo trial with Libtayo. The setback comes a year after the company drew buzz for the combo with its potential to add depth to the immunotherapy armamentarium.
TEL AVIV, Israel, July 17, 2023 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial stage biopharmaceutical company pursuing life-changing therapies for certain cancers and rare diseases, today announced the initiation of a randomized, investigator-initiated Phase 2 clinical trial in first line metastatic pancreatic cancer based on preliminary data from the single-arm pilot phase. The combination drug trial includes the investigational candidate motixafortide. Sponsored by Columbia University, the amended study will modify a single-arm trial whose original design called for expansion to an additional 30 patients if data from a pilot phase of 10 patients was encouraging (defined as ?3 patients with partial response by RECIST criteria). The amended randomized study will compare combination treatment with the Company's CXCR4 inhibitor (motixafortide), a PD-1 inhibitor (cemiplimab), and chemotherapy (gemcitabine, nab-paclitaxel) to chemotherapy alone in a larger number of patients (n= 102).
WALTHAM, Mass.--(BUSINESS WIRE)--Palleon Pharmaceuticals, a clinical-stage company pioneering glyco-immunology drug development to treat cancer and inflammatory diseases, today announced that the first patient has been dosed in the combination therapy cohort of the Phase 1/2 clinical trial for E-602, its lead candidate from the EAGLE (Enzyme Antibody Glyco-Ligand Editing) oncology platform. The GLIMMER-01 (Glycan-Mediated Immune Regulation) trial is designed to study E-602 as a monotherapy and in combination with cemiplimab (anti-PD-1) in patients with advanced cancers.
OEGSTGEEST, The Netherlands, June 6, 2023 /PRNewswire/ -- ISA Pharmaceuticals B.V., a clinical-stage biotechnology company developing immunotherapies to treat cancers and serious infectious diseases, presented the first clinical data of the combination of ISA101b (peltopepimut-S) and Regeneron's anti-PD-1 Libtayo® (cemiplimab) at the ASCO annual meeting in Chicago.
OEGSTGEEST, Netherlands, May 25, 2023 /PRNewswire/ -- ISA Pharmaceuticals B.V., a clinical-stage biotechnology company developing immunotherapies to treat cancers and serious infectious diseases, today announces that it will present the first clinical data of the combination of ISA101b and Regeneron's PD-1 inhibitor Libtayo® (cemiplimab) in patients with recurrent metastatic Human Papilloma Virus type 16 (HPV16) induced head and neck cancers who progressed on pembrolizumab or nivolumab.
Data demonstrate objective response rates from 56% to 63% across three independent cohorts of advanced melanoma patients about double the rate historically seen with anti-PD-1 alone in similar...